Drug Profile
Research programme: controlled-release therapeutics - Novartis/OctoPlus
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Novartis; OctoPlus
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Netherlands (Controlled release)
- 27 Feb 2013 OctoPlus has been acquired by Dr Reddys Laboratories
- 13 Sep 2010 Preclinical development is ongoing in the Netherlands